iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.80−0.00 (-0.11%)
Close on Nov 20, 2026Market cap $51.45MP/E –Yield –
iBio gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
iBio's gross profit for the twelve months ending Jun 30, 2022 was $2.17M, up 138.4% year over year. For fiscal 2022 it was $2.17M, up 138.4% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | $2.17M | +138.4% |
| FY2021 | Jun 30, 2021 | $909.00K | -2.8% |
| FY2020 | Jun 30, 2020 | $935.00K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $46.00K | -90.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $1.90M | +525.4% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $304.00K | -63.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $272.00K | +2620.0% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $494.00K | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $303.00K | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $821.00K | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $10.00K | – |
See a number that looks wrong?